(RTTNews) - Beximco Pharmaceuticals Limited (BXP.L) announced the launch of generic molnupiravir, an oral antiviral drug for symptomatic COVID-19 recently developed by Merck, Sharp & Dohme and ...
(Reuters) -A Bangladeshi drugmaker will soon begin selling the world's first generic version of Merck's COVID-19 pill, molnupiravir, which has been touted as a potential game-changer in the fight ...
(Reuters) - The Bill & Melinda Gates Foundation said on Wednesday it would spend up to $120 million to kick-start development of generic versions of Merck & Co's oral COVID-19 treatment to help ensure ...
Weighing three outpatient treatments for COVID-19, the drug cost watchdog Institute for Clinical and Economic Review (ICER) has determined that Pfizer’s Paxlovid, Merck and Ridgeback Biotherapeutics’ ...
KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that a total of approximately 3.1 million ...
Beximco Pharmaceuticals Limited (Beximco Pharma), the fast-growing manufacturer of generic pharmaceutical products and API, announces the launch of the world's first generic molnupiravir, an oral ...
As coronavirus cases rage in India, Merck announced that it has entered into non-exclusive voluntary licensing agreements with five manufacturers of generic drugs in that country to speed and expand ...
KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that the U.S. Food and Drug ...
BENGALURU, Oct 8 (Reuters) - Two Indian drugmakers have requested permission to end late-stage trials of their generic versions of Merck & Co's (MRK.N), opens new tab promising experimental oral ...
Jan. 20 (UPI) --More than two dozen generic drugmakers have an agreement to produce an antiviral COVID-19 pill by Merck and supply it to more than 100 developing countries to help them fight the ...
Indian drugmaker Dr Reddy's Laboratories Ltd will launch its generic version of Merck's antiviral COVID-19 pill, molnupiravir, and price it at 35 rupees ($0.4693) per capsule, a company spokesperson ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback